Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 3 (2006), Issue 7 (July)

1. Differentiation of human airway epithelia is dependent on erbB2.
   Am J Physiol Lung Cell Mol Physiol, 291(2): L175-80. [Abstract] [Full-text]
2. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
   Cancer. [Abstract] [Full-text]
3. Potential use of humanized antibodies in the treatment of breast cancer.
   Expert Rev Anticancer Ther, 6(7): 1065-74. [Abstract] [Full-text]
4. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients.
   Breast Cancer Res Treat, 98(2): 179-84. [Abstract] [Full-text]
5. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
   Cancer Cell, 10(1): 25-38. [Abstract] [Full-text]
6. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
   Cancer Res, 66(14): 7245-52. [Abstract] [Full-text]
7. Targeted therapies in combination with chemotherapy in non-small cell lung cancer.
   Clin Cancer Res, 12(14): 4451s-4457s. [Abstract] [Full-text]
8. Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer.
   Clin Cancer Res, 12(14): 4436s-4440s. [Abstract] [Full-text]
9. Her2-targeted therapies in non-small cell lung cancer.
   Clin Cancer Res, 12(14): 4377s-4383s. [Abstract] [Full-text]
10. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
    Clin Cancer Res, 12(14): 4192-9. [Abstract] [Full-text]
11. The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer.
    Expert Opin Pharmacother, 7(12): 1617-25. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.